Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2004

View Archived Issues

Tarceva accepted onto FDA Pilot 1 Program

Xenon Genetics changes name to Xenon Pharmaceuticals

Large Scale Biology and the U. of Louisville collaborate on HPV-associated cancers

Phase Ic results of PYY3-36 nasal spray for obesity

Alcon files second portion of Retaane rolling NDA

Enrollment under way in two phase III Leukine studies for Crohn's disease

New phase II study of Telcyta combination front-line treatment of NSCLC

Merck & Co. and Alnylam collaborate on RNAi therapeutics for ocular diseases

BioXell acquires from Roche rights to new indications for BXL-628

Eisai launches Apnission in Japan

Acetylcholinesterase inhibitor ITH-4012 shows calcium promoting and neuroprotective activity

Centocor and Fujisawa discontinue codevelopment of abciximab in Japan

CoTherix submits NDA for Ventavis

OPi and Vaccinex establish antibody collaboration

European orphan drug designation recommended for Surfaxin

Striant SR submitted for mutual recognition procedure in Europe

Mitsubishi Pharma describes series of cyclic amide derivatives

COX-2 inhibitors presented by CJ Corporation

Achillion Pharmaceuticals claims inhibitors of hepatitis C virus replication

Ubiquitination inhibitors in early development at Rigel

BMS scientists prepare and test novel selective androgen receptor modulators

Sumitomo discloses agents for fibrosis in patent literature

Modafinil beneficial in patients with schizophrenia

Development of LJP-1082 and LJP-394 reviewed

Novel potent and selective T-type calcium channel blockers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...